1	SARS-CoV-2 antibody prevalence and determinants
2	of six ethnic groups living in Amsterdam, the Netherlands:
3	a population-based cross-sectional study, June-October 2020
4	Running title
5	SARS-CoV-2 seroprevalence and ethnicity
6	Authors
7	Liza Coyer ^{1,2} , Anders Boyd ^{1,3} , Janke Schinkel ⁴ , Charles Agyemang ⁵ , Henrike Galenkamp ⁵ , Anitra D M
8	Koopman ⁵ , Tjalling Leenstra ¹ , Eric P Moll van Charante ^{5,7} , Bert-Jan H van den Born ⁸ , Anja Lok ⁹ ,
9	Arnoud Verhoeff ^{10,11} , Aeilko H Zwinderman ¹² , Suzanne Jurriaans ⁴ , Lonneke A van Vught ^{7,13,14} , Karien
10	Stronks ⁵ , Maria Prins ^{1,2}
11	Affiliations
12	¹ Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the
13	Netherlands
14	² Amsterdam UMC, Department of Infectious Diseases, Amsterdam Infection and Immunity (AII),
15	University of Amsterdam, Amsterdam, the Netherlands
16	³ Stichting HIV Monitoring, Amsterdam, the Netherlands
17	⁴ Amsterdam UMC, Department of Medical Microbiology, University of Amsterdam, Amsterdam,
18	the Netherlands
19	⁵ Amsterdam UMC, Department of Public and Occupational Health, Amsterdam Public Health
20	Research Institute, University of Amsterdam, Amsterdam, the Netherlands
21	⁶ Amsterdam UMC, Department of Epidemiology and Biostatistics, Amsterdam Public Health
22	Research Institute, VU University Amsterdam, Amsterdam, the Netherlands NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21252788; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

- 23 ⁷ Amsterdam UMC, Department of General Practice, Amsterdam Public Health Research Institute,
- 24 University of Amsterdam, Amsterdam, the Netherlands
- ⁸ Amsterdam UMC, Department of Vascular Medicine, Amsterdam Cardiovascular Sciences,
- 26 University of Amsterdam, Amsterdam, the Netherlands
- ⁹ Amsterdam UMC, Department of Psychiatry, Amsterdam Public Health Research Institute, Center
- 28 for Urban Mental Health, University of Amsterdam, Amsterdam, the Netherlands
- ¹⁰ Department of Epidemiology, Health Promotion & Healthcare Innovation, Public Health Service
- 30 of Amsterdam, Amsterdam, the Netherlands
- ¹¹ Department of Sociology, University of Amsterdam, Amsterdam, the Netherlands
- 32 ¹² Amsterdam UMC, Department of Clinical Epidemiology, Biostatistics and Bioinformatics,
- 33 University of Amsterdam, Amsterdam, the Netherlands
- ¹³ Amsterdam UMC, Center for Experimental Molecular Medicine, University of Amsterdam,
- 35 Amsterdam, the Netherlands
- 36 ¹⁴ Amsterdam UMC, Department of Intensive Care Medicine, University of Amsterdam, Amsterdam,
- 37 the Netherlands

38 Contact details corresponding author

- 39 Liza Coyer
- 40 Nieuwe Achtergracht 100
- 41 1018 WT Amsterdam
- 42 Phone: +31 20 555 3873
- 43 Email: lcoyer@ggd.amsterdam.nl

44 Keywords

45 HELIUS study; SARS-CoV-2; COVID-19; infection, seroprevalence; serology, antibody; ethnicity

46 Abstract

47 Background

- 48 Ethnic minorities have higher rates of SARS-CoV-2 diagnoses, but little is known about ethnic
- 49 differences in past exposure. We aimed to determine whether prevalence and determinants of
- 50 SARS-CoV-2 exposure varied between six ethnic groups in Amsterdam, the Netherlands.

51 Methods

- 52 Participants aged 25-79 years enrolled in a population-based prospective cohort were randomly
- 53 selected within ethnic groups and invited to test for SARS-CoV-2-specific antibodies and answer
- 54 COVID-19 related questions. We estimated prevalence and determinants of SARS-CoV-2 exposure
- within ethnic groups using survey-weighted logistic regression adjusting for age, sex and calendar

56 time.

57 Results

- 58 Between June 24-October 9, 2020, we included 2497 participants. Adjusted SARS-CoV-2
- 59 seroprevalence was comparable between ethnic-Dutch (25/498; 5.5%, 95%CI=3.2-7.9), South-Asian
- 60 Surinamese (22/451; 4.8%, 95%Cl=2.1-7.5), African Surinamese (22/400; 8.2%, 95%Cl=3.0-13.4),
- 61 Turkish (30/408; 7.8%, 95%Cl=4.3-11.2) and Moroccan (32/391; 7.0%, 95%Cl=4.0-9.9) participants,
- 62 but higher among Ghanaians (95/327; 26.5%, 95%Cl=18.7-34.4). 57.1% of SARS-CoV-2-positive
- 63 participants did not suspect or were unsure of being infected, which was lowest in African
- 64 Surinamese (18.2%) and highest in Ghanaians (90.5%). Determinants of SARS-CoV-2 exposure
- varied across ethnic groups, while the most common determinant was having a household member
- suspected of infection. In Ghanaians, seropositivity was associated with older age, larger household
- 67 sizes, living with small children, leaving home to work and attending religious services.

68 Conclusions

20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

- No remarkable differences in SARS-CoV-2 seroprevalence were observed between the largest 69
- 70 ethnic groups in Amsterdam after the first wave of infections. The higher infection seroprevalence
- observed among Ghanaians, which passed mostly unnoticed, warrants wider prevention efforts and 71
- 72 opportunities for non-symptom-based testing.

20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

73 Introduction

- 74 Data from the United Kingdom (UK) and United States (US) suggest that certain ethnic minority
- populations have been disproportionally affected by the coronavirus disease 2019 (COVID-19),
- 76 caused by SARS-CoV-2. In both countries, a relatively higher number of SARS-CoV-2 polymerase
- chain reaction (PCR)-positive or clinically-diagnosed COVID-19 cases were observed among ethnic
- 78 minority groups, particularly people of African and Asian descent.[1-3] The underlying causes for
- 79 these disparities might include work-related exposure, housing conditions, access to healthcare,
- 80 help-seeking behavior, and language proficiency.[4-6]

81 Little is known about ethnic differences in SARS-CoV-2 infections outside the UK and US. This is of

82 particular concern for larger cities in Europe, including the Dutch capital Amsterdam, where half the

83 population comprises migrants, including people with foreign-born parents.[7] Amsterdam

84 witnessed its first confirmed case of SARS-CoV-2 on February 29, 2020 and by December 31, 2020,

85 there were more than 50,000 confirmed infections, 1300 COVID-19-related hospitalizations and 500

86 COVID-19-related deaths.[8] If SARS-CoV-2 infection prevalence is increased in specific ethnic

87 groups, targeted prevention measures could be instated to help minimize the risk of further

88 transmission.

89 Ethnic differences in SARS-CoV-2 infection prevalence could be studied using COVID-19

90 notification registries. However, since the testing policy in the Netherlands has changed several

91 times and until June 1, 2020, testing was largely restricted to symptomatic health care workers or

92 those living or working in long-term care facilities, these data are prone to differential testing

93 uptake. Ethnic differences in testing uptake could be further exacerbated by testing access,

94 willingness to test and disease perceptions. Another limitation of registries is that migration

95 background is often missing. Other data are therefore needed to estimate seroprevalence within

96 specific ethnic groups in Amsterdam.

It is made available under a CC-BY-NC-ND 4.0 International license . 20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

- 97 The Healthy life in an Urban Setting (HELIUS) study is a large, population-based cohort study
- 98 among six different ethnic groups, which was established with the aim to investigate mechanisms
- 99 underlying the impact of ethnicity on communicable and non-communicable diseases.[9] From
- 100 individuals actively enrolled in this study, we determined the prevalence and determinants of
- 101 exposure to SARS-CoV-2 between the largest ethnic groups in Amsterdam.

102 Methods

103 Study design and population

104 The HELIUS study is a multiethnic cohort study conducted in Amsterdam, the Netherlands, which

- 105 focuses on cardiovascular disease, mental health, and infectious diseases. Detailed procedures have
- 106 been previously described.[9] Briefly, HELIUS includes persons of Dutch, South-Asian Surinamese,
- 107 African Surinamese, Ghanaian, Moroccan, and Turkish origin, aged between 18 and 70 years at
- 108 inclusion. A random sample of persons, stratified by ethnic origin, was taken from the municipality
- 109 register of Amsterdam and subjects were invited to participate. Between January 2011 and
- 110 December 2015, a total of 24,789 individuals were included.[9] Participants filled in a self-
- administered questionnaire and underwent a physical examination during which biological samples
- 112 were obtained. Ethical approval for the HELIUS study was obtained from the Academic Medical
- 113 Center Ethical Review Board. All participants provided written informed consent.
- 114 Ethnicity was defined according to the country of birth of the participant and their parents.[9]
- 115 Participants were considered to be of non-Dutch ethnic origin if (i) they were born abroad and had
- at least one parent born abroad (first generation) or (ii) they were born in Netherlands but both their
- 117 parents were born abroad (second generation). Participants of Dutch origin were born in the
- 118 Netherlands with both parents who were born in the Netherlands. Surinamese participants were
- 119 further classified as African Surinamese, South-Asian Surinamese, and Javanese/other/unknown
- 120 Surinamese, based on self-reporting.

A cross-sectional, serological substudy was performed in participants of the HELIUS study from 24 June to 9 October 2020. Participants were randomly selected within each ethnic group and asked to participate in the substudy. Serum samples for assessment of SARS-CoV-2 antibodies were collected by venipuncture and stored at -20°C. Trained interviewers asked participants questions on uptake of COVID-19-related prevention measures, potential exposure, infection, symptoms and disease.

20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

127 Outcomes

128 SARS-CoV-2 exposure was determined by the presence of SARS-CoV-2 antibodies. SARS-CoV-2-

- 129 specific antibodies were determined using the WANTAI SARS-CoV-2 Ab Elisa (Wantai Biological
- 130 Pharmacy Enterprise Co., Beijing, China) according to the manufacturer's instructions. This Elisa
- detects IgA, IgM and IgG against the receptor binding domain of the S-protein of SARS-CoV-2.[10]

132 Determinants

133 We defined the following potential determinants: from the baseline visit of the HELIUS study–

demographics (i.e. age, sex, ethnicity, migration generation, city district), socio-economic factors

- 135 (i.e. educational level, working status, occupational level, number of people in household), access-
- to-healthcare indicators (i.e. proficiency with Dutch language, health literacy); from the COVID-19

137 substudy visit–job setting, household members, suspected being infected, thinking household

- 138 member/steady partner was infected, household member hospitalized for COVID-19, type of
- people living in household, travelling abroad in 2020 and COVID-19 behaviors in the past week (i.e.
- 140 number of times leaving the house, type of locations visited, number of visitors, frequency of using
- 141 public transportation).

142 Statistical analysis

143 SARS-CoV-2 seroprevalence, along with 95% confidence intervals (CI), was modeled per ethnic 144 group using univariable logistic regression. Seroprevalence was then modeled per ethnic group while correcting for sampling, accounting for the population structure of ethnic groups in 145 Amsterdam (i.e. post-stratification), and adjusting for differences in age, sex and calendar time 146 (before/after 15 August 2020, based on the onset of the second wave of SARS-CoV-2 infections in 147 148 the Netherlands[8]) between ethnic groups. For sampling, the probability of being invited for the 149 COVID-19 substudy (as the proportion of participants invited among those in active follow-up in the 150 parent study) was calculated, as was the conditional probability of participating in the COVID-19 151 substudy (given the participant's ethnicity, age, educational level, working status and health

20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

152	literacy). The product of the two probabilities was taken and the inverse of this result, standardized
153	to one, was used as a sampling weight. For post-stratification, a weight was assigned corresponding
154	to the proportion representing the Amsterdam population of each stratum of age (20-44, 45-54, 55-
155	59, 60-79 years), sex (male, female) and ethnicity (Surinamese, Ghanaian, Moroccan, Turkish,
156	Dutch). Sampling and post-stratification weights were placed in a multivariable logistic regression
157	model with covariates ethnicity, age, sex, and calendar time. Given the weighting scheme of this
158	study, variance was calculated with the designed-based Taylor series linearization method using the
159	'svy' commands in STATA. Differences between ethnic groups were tested in the model using the
160	Wald χ2 test.
161	Seroprevalence was regressed on age (in restricted cubic splines with 3 knots) with sample and
162	post-stratification weights, within subpopulations of ethnic groups. The mean and 95%CI of
163	predicted seroprevalence was plotted over age in years.
164	To identify determinants of past SARS-CoV-2 infection within ethnic groups, univariable
165	associations between potential determinants and SARS-CoV-2 seropositivity were evaluated. The

166 odds ratios (OR) comparing the odds of seroprevalence across levels of each determinant, and their

167 95% confidence intervals (CI), were estimated using logistic regression. P-values were obtained

168 using the Wald χ^2 test. All covariates with a *P*-value ≤ 0.2 in univariable analyses were then included

in a multivariable model and after assessing covariate distributions and collinearity, variables with a

170 *P*-value≥0.05 above this threshold were removed in backwards-stepwise fashion until only variables

171 with a *P*-value<0.05 were retained in a final multivariable model. All models included sampling and

172 post-stratification weights. We forced calendar time in all models.

173 Statistical significance was defined at a *P*-value<0.05. All analyses were conducted using Stata 15.1

174 (StataCorp, College Station, TX, USA).

175 Results

176 Study population

Of the 16,889 HELIUS participants who were in active follow-up in 2019-2020, 11,080 (65.6%) were 177 178 invited (Figure 1). Of these, 2497 (22.5%) were included in the COVID-19 substudy. The response 179 rate varied across ethnic groups, from 15.3-17.2% among Ghanaian, Turkish or Moroccan participants to 49.9% among Dutch participants. Detailed information on differences between 180 HELIUS participants who were and were not invited, and between invited participants who were 181 182 and were not included, are presented in Supplementary Table 1. Briefly, invited individuals who were included had obtained a slightly higher educational level, were more likely to be employed and 183 184 were more likely to have adequate health literacy level compared to those who were invited but not 185 included. Number included per month within ethnic groups is presented in Supplementary Figure 1. Of 2497 186 187 included participants, 503 (20.1%) were of Dutch origin, 453 (18.1%) South-Asian Surinamese, 407 188 (16.3%) African Surinamese, 331 (13.3%) Ghanaian, 409 (16.4%) Turkish and 394 (15.8%) Moroccan

189 (Supplementary Table 1, Table 1). The median age of included participants was 54 (interquartile

range [IQR]: 44-61) and 56.6% were female. In the 1994 participants of non-Dutch origin, the

191 percentage of first-generation migrants was lowest in the Turkish group (74.8%) and highest in the

192 Ghanaian group (98.2%). Dutch participants were the most likely to have a higher vocational or

university degree (67.0%) and be employed (75.5%) compared to other ethnicities.

194 SARS-CoV-2 seroprevalence

195 Of 2497 included, 2483 (99.4%) participants had a SARS-CoV-2 antibody test result. Of these 2483,

196 226 were positive, 2249 negative and 8 had an equivocal test result. The distribution of signal-to-

197 cutoff ratios for positive test results is shown per ethnic group in Supplementary Figure 2. The

198 proportion with a positive result did not increase over time in any of the ethnic groups, except for

199 the South-Asian Surinamese group (Supplementary Figure 1).

medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21252788; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pernetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

- 200 Unadjusted and adjusted seroprevalence estimates per ethnic group are provided in Figure 2 and
- 201 Supplementary Table 2. Adjusted seroprevalence was comparable between the Dutch (5.5%,
- 202 95%CI=3.2-7.9), South-Asian Surinamese (4.8%, 95%CI=2.1-7.5), African Surinamese (8.2%,
- 203 95%CI=3.0-13.4), Turkish (7.8%, 95%CI=4.3-11.2) and Moroccan (7.0%, 95%CI=4.0-9.9) groups, but
- higher in the Ghanaian group compared to all other groups (26.5%, 95%Cl=18.7-34.4, P<0.001).
- 205 Figure 3 shows adjusted seroprevalence estimates as a function of age in years for each ethnic
- group. In the African Surinamese group, seroprevalence decreased with age. In the Ghanaian group,
- the highest seroprevalence was observed between the ages of 50-55 years.
- 208 COVID-19-related symptoms
- 209 Table 2 describes SARS-CoV-2-related characteristics of included participants. Of 2497 participants,
- 210 348 (13.9%) suspected being infected with SARS-CoV-2, 2144 (85.9%) did not suspect or were
- 211 unsure of being infected. 90.5% of Ghanaian participants who tested positive did not suspect or
- 212 were unsure of being infected, mainly because most of these individuals had not experienced
- 213 symptoms (58.7%). SARS-CoV-2 positive individuals from other ethnic groups more frequently
- suspected being infected (range 59.1% to 81.8%).
- 215 Determinants of SARS-CoV-2 seropositivity per ethnic group
- 216 Univariable analysis of determinants of SARS-CoV-2 seropositivity is presented per ethnic group in
- 217 Supplementary Tables 2-7. In multivariable analysis (Figure 4), having a household member
- 218 suspected of infection was associated with SARS-CoV-2 seropositivity in Dutch, South-Asian
- 219 Surinamese, Turkish and Moroccan participants. Recently traveling abroad was associated with
- 220 seropositivity in Dutch and South-Asian Surinamese participants. In Ghanaian participants, older
- age, increasing household size, living with children \leq_3 years old, and leaving home to work and
- 222 attending religious services were associated with SARS-CoV-2 seropositivity. Increased odds for
- 223 SARS-CoV-2 seropositivity were also observed for leaving home to pick up medication or visiting a
- doctor in the past week (Dutch participants), living with other adults (African Surinamese), having

20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

- 225 had ≥2 unique visitors in the past week (African Surinamese), leaving home to walk or exercise
- 226 outside and using public transportation in the past week (Turkish participants) and occupational
- level (Moroccan participants). 227

20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

228 Discussion

229	After the first wave of the SARS-CoV-2 epidemic, we observed no evidence of ethnic disparities in
230	past SARS-CoV-2 infection between the six largest ethnic groups residing in Amsterdam, The
231	Netherlands, with the noteworthy exception of individuals of Ghanaian origin. We estimated that
232	26% of the adult Ghanaian group had developed SARS-COV-2 antibodies, compared to 5-8% of the
233	other adult ethnic groups. Increased risk of past infection was present among individuals who
234	reported a household member suspected of infection in four of the six groups. Amongst other
235	factors, leaving home to work and attending religious services were associated with seropositivity in
236	Ghanaian individuals, while using public transportation was associated with seropositivity in Turkish
237	individuals. Determinants differed between ethnicities, hence demonstrating that broad
238	generalizations of some SARS-CoV-2-related determinants might not be appropriate for individual
239	ethnic groups.
239 240	ethnic groups. Among the determinants of SARS-CoV-2 seropositivity, work and travelling to work, most likely via
240	Among the determinants of SARS-CoV-2 seropositivity, work and travelling to work, most likely via
240 241	Among the determinants of SARS-CoV-2 seropositivity, work and travelling to work, most likely via public transportation, represents a common theme in individuals of non-Dutch origin. Working from
240 241 242	Among the determinants of SARS-CoV-2 seropositivity, work and travelling to work, most likely via public transportation, represents a common theme in individuals of non-Dutch origin. Working from home was one of the first preventive measures introduced in the Netherlands to mitigate spread of
240 241 242 243	Among the determinants of SARS-CoV-2 seropositivity, work and travelling to work, most likely via public transportation, represents a common theme in individuals of non-Dutch origin. Working from home was one of the first preventive measures introduced in the Netherlands to mitigate spread of SARS-CoV-2.[11] However, this was not feasible for individuals with lower professional levels and
240 241 242 243 244	Among the determinants of SARS-CoV-2 seropositivity, work and travelling to work, most likely via public transportation, represents a common theme in individuals of non-Dutch origin. Working from home was one of the first preventive measures introduced in the Netherlands to mitigate spread of SARS-CoV-2.[11] However, this was not feasible for individuals with lower professional levels and jobs requiring physical presence, many of whom were of non-Dutch origin. Interestingly, Moroccan
240 241 242 243 244 245	Among the determinants of SARS-CoV-2 seropositivity, work and travelling to work, most likely via public transportation, represents a common theme in individuals of non-Dutch origin. Working from home was one of the first preventive measures introduced in the Netherlands to mitigate spread of SARS-CoV-2.[11] However, this was not feasible for individuals with lower professional levels and jobs requiring physical presence, many of whom were of non-Dutch origin. Interestingly, Moroccan individuals in the missing occupation category appeared to be more often seropositive. Previous
240 241 242 243 244 245 246	Among the determinants of SARS-CoV-2 seropositivity, work and travelling to work, most likely via public transportation, represents a common theme in individuals of non-Dutch origin. Working from home was one of the first preventive measures introduced in the Netherlands to mitigate spread of SARS-CoV-2.[11] However, this was not feasible for individuals with lower professional levels and jobs requiring physical presence, many of whom were of non-Dutch origin. Interestingly, Moroccan individuals in the missing occupation category appeared to be more often seropositive. Previous research suggests that the health of individuals in this category resembles that of individuals with

Although attending religious services was asked only for the past week and infections may have occurred as early as in March 2020, exposure to SARS-CoV-2 during attendance at religious services might have driven many of the past infections observed in the Ghanaian group. Religious services, along with demonstrations, were allowed to continue without a maximum number of attendees, as

20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

253	stipulated by Dutch law,[13] which could have fostered further spread of SARS-CoV-2. Many places
254	of worship did, however, implement social distancing measures. A nationwide study demonstrated
255	similar findings in that Orthodox-Reformed Protestants were at increased risk for SARS-CoV-2
256	seropositivity during the first wave of the pandemic.[14] Increased infection risk for people
257	attending religious services has also been demonstrated in studies from other countries.[15-17]
258	Strikingly, 90% of Ghanaians with SARS-CoV-2 antibodies did not suspect or were unsure of being
259	infected, many because they did not report experiencing any COVID-19-related symptoms. This is
260	in stark contrast to other ethnic groups in which most SARS-CoV-2 positive individuals had
261	suspected of being infected. If these infections were indeed asymptomatic in Ghanaians, many
262	could have been completely unaware of their infection and as a result, might have carried out their
263	normal routines despite unknowingly continuing transmission. The dense clustering of Ghanaians in
264	the South-East city district of Amsterdam might have also accelerated transmission, as we
265	unknowingly may have sampled a cluster of infections within a specific neighbourhood or religious
266	center. Nevertheless, there were no infection clusters within Ghanaian individuals identified during
267	the first wave by the local Public Health Service (personal communication T. Leenstra, January 27,
268	2021), when SARS-CoV-2 PCR testing was restricted. Our study clearly indicates that to reduce
269	ongoing and unnoticed transmission of SARS-CoV-2, expanded testing needs to include those
270	groups in which the proportion of asymptomatic individuals might be high, such as the Ghanaian
271	residents of Amsterdam.

272 Since data from Ghana on SARS-CoV-2 seroprevalence and proportion of asymptomatic infection are limited, we cannot make any distinction on whether our finding reflects the epidemiology in the 273 country of origin or is specific to Ghanaian individuals in the Netherlands. One modelling study 274 275 suggests that Ghana is one of the four most affected African countries in terms of cases, but has a 276 relatively low death rate.[18] A study among Kenyan blood donors found a surprisingly high seroprevalence (4.3%) from what can be inferred by the low number of COVID-19-related 277

20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

278 hospitalisations and deaths.[19] Further research is needed to clarify the role of symptom burden,

279 earlier exposure to coronaviruses, or differences in genetic vulnerability to symptoms in explaining

the seemingly high proportion of asymptomatic cases in Ghanaians.[20,21]

281 Having a household member suspected of being infected was the most common and consistent

282 determinant of seropositivity. This finding supports observations that during periods of more

283 extensive lock-downs, most transmissions occur in household settings and is related to

symptomatic infection, age distribution and social interactions within households.[22-24] Other

285 household determinants of seropositivity were observed in specific ethnic groups and included

living with other adults, living with children \leq_3 years old, and larger household sizes.

287 In the Netherlands, a series of restrictions was introduced in mid-March, when the spread of SARS-

288 CoV-2 was still limited.[11] The finding that seroprevalence did not differ between ethnic groups,

other than Ghanaian, implies that these restrictive measures were able to prevent the spread of

290 infection equally across ethnicities. Furthermore, additional data from individuals participating in

the parent HELIUS study showed that non-ethnic Dutch groups in general were as likely as ethnic-

292 Dutch to adhere to prevention measures (personal communication F. Chilunga, January, 27 2021). It

should be mentioned that our results also stem from a setting where economic inequalities are not

294 prohibitive to healthcare access.[25]

295 In comparison to the seroprevalence estimates, people from large ethnic groups (Netherlands 296 Antilles, Morocco, Surinam, Turkey, Ghana) had increased hospitalisation rates compared to ethnic 297 Dutch individuals living in Amsterdam between February and May 2020, [26] as shown in other 298 settings.[2,3] In addition, individuals with a migration background living in the Netherlands had a 299 higher excess mortality during the first six weeks of the COVID-19 pandemic.[27] Our data suggest 300 that, apart from Ghanaians, the increased rates of hospitalisations and deaths in non-Dutch ethnic groups during this period cannot be explained by a higher infection rate. The severity of COVID-19 301 302 can be impacted to a large extent by underlying comorbidities,[28] which vary across ethnic

20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

303	aroups[9]	and could expla	in differences	s in severity.[20	9] Healthcare inec	ualities, racism,

304 stigmatisation and discrimination witnessed by ethnic minorities and differences in healthcare

305 seeking-behaviour may provide additional explanations for these disparities.[30-34]

306 Strengths of our study include population-based sampling, with a large number of participants from 307 the major ethnic groups living in Amsterdam, representing various levels of socioeconomic status; 308 measuring seroprevalence via antibodies in individuals with and without previous COVID-19-related 309 symptoms; and obtaining individual-level determinants of infection. Nonetheless, there are several 310 limitations. First, our study includes a random subsample of HELIUS participants and there may be 311 selection bias. Undocumented people and other ethnic groups living in Amsterdam were not included in the parent study. Second, participants in our substudy may have been more concerned 312 313 about their health compared to non-participants. Notwithstanding the differential response rate between ethnicities in this substudy, the distribution of characteristics was largely similar between 314 included and non-included HELIUS participants. Our estimates, corrected for sampling and post-315 316 stratification, were also close to those from a nationwide study that included mainly people of 317 Dutch origin and revealed a 6% seroprevalence among the Amsterdam population in June 2020.[35] Data were also collected over a span of 4 months, which reflects different points of the epidemic, 318 319 and thus the timing of testing could bias estimates. We attempted to mitigate this issue by 320 adjusting for calendar time. Furthermore, prevention measures remained mostly the same and nationwide incidence was quite stable during this period, thereby limiting the effect of this 321 bias.[8,36] Third, as this study was cross-sectional and infection occurred in the past, it is difficult to 322 323 make any causal inference with respect to determinants. Fourth, fear of stigmatization or 324 consequences for work might have led to an underreporting of suspected past infection and symptoms, particularly among Ghanaians. Finally, circulating SARS-CoV-2 antibodies could have 325 326 disappeared after infection, [37, 38] although this was probably limited during the study period,[39,40] and individuals could not participate in this substudy if they were experiencing 327 COVID-19-related symptoms, both of which likely led to underestimated seroprevalence. 328

It is made available under a CC-BY-NC-ND 4.0 International license . 20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

329 In conclusion, most ethnic groups displayed comparable seroprevalence after the first SARS-CoV-2

- 330 wave in Amsterdam, yet the substantially higher prevalence among the smaller Ghanaian
- 331 population, possibly infections without symptoms, is of concern. Targeted prevention campaigns
- addressing the needs of specific ethnic groups and expanding testing opportunities are urgently
- 333 warranted. In addition, prevention measures for those who cannot work from home should be
- intensified, also by bringing to light the employer's role in reducing COVID-19 transmissions.

20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

335 Author contributions

- 336 MP, KS, JS and CA conceived, designed or oversaw the study. HG, AK and JS were involved in the
- 337 acquisition of data. LC and AB conducted the statistical analysis. LC, AB and MP drafted the
- 338 manuscript. All authors read and approved the final manuscript.

339 **Declaration of interests**

340 The authors declare that they have no competing interests related to the project.

341 Data sharing

- 342 The HELIUS data are owned by the Amsterdam UMC, location AMC, in Amsterdam, The
- 343 Netherlands. Any researcher can request the data by submitting a proposal to the HELIUS
- 344 Executive Board as outlined at http://www.heliusstudy.nl/en/researchers/collaboration, by email:
- heliuscoordinator@amsterdamumc.nl. The HELIUS Executive Board will check proposals for
- 346 compatibility with the general objectives, ethical approvals and informed consent forms of the
- 347 HELIUS study. There are no other restrictions to obtaining the data and all data requests will be
- 348 processed in the same manner.

349 Funding

- 350 This work was supported by ZonMw (10430022010002) and the Public Health Service of
- 351 Amsterdam. The HELIUS study is conducted by Amsterdam UMC, location Academic Medical
- 352 Center and the Public Health Service of Amsterdam. Both organizations provided core support for
- HELIUS. The HELIUS study is also funded by the Dutch Heart Foundation (2010 T084), ZonMw
- 354 (200500003), the European Union (FP-7) (278901), and the European Fund for the Integration of
- 355 non-EU immigrants (EIF) (2013EIF013).

356 Acknowledgements

20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

- The authors would like to acknowledge the HELIUS COVID-19 study participants for their 357
- 358 contribution and the HELIUS team for data collection and management. They would also like to
- thank Anton Janssen for providing population tables. 359

medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21252788; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

360 **References**

- 361 1. Public Health England. Disparities in the risk and outcomes of COVID-19, 2020.
- 362 2. Sze S, Pan D, Nevill CR, Gray LJ, Martin CA, Nazareth J, et al. Ethnicity and clinical
- 363 outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2020;29:100630.
- 364 3. Indseth T, Grøsland M, Arnesen T, Skyrud K, Kløvstad H, Lamprini V, et al. COVID-19 among
- 365 immigrants in Norway, notified infections, related hospitalizations and associated mortality: A
- register-based study. Scand J Public Health. 2021;49(1):48-56.
- 367 4. Public Health England. Beyond the data: Understanding the impact of COVID-19 on BAME
 368 groups, June 2020.
- 369 5. Bhala N, Curry G, Martineau AR, Agyemang C, Bhopal R. Sharpening the global focus on
- ethnicity and race in the time of COVID-19. The Lancet. 2020;395(10238):1673-6.
- 371 6. Martin CA, Jenkins DR, Minhas JS, Gray LJ, Tang J, Williams C, et al. Socio-demographic
- 372 heterogeneity in the prevalence of COVID-19 during lockdown is associated with ethnicity and
- household size: Results from an observational cohort study. EClinicalMedicine. 2020;25:100466.
- 374 7. Statistics Netherlands (CBS). Bevolking; leeftijd, migratieachtergrond, geslacht, regio, 1 jan.
 375 1996-2020. Available from:
- 376 https://opendata.cbs.nl/statline/#/CBS/nl/dataset/37713/table?fromstatweb. Accessed 6 January
 377 2021.
- 8. National Institute for Public Health and the Environment, Ministry of Health, Walfare and
- 379 Sport. Current information about COVID-19 (novel coronavirus) 2020. Available from:
- 380 https://www.rivm.nl/en/novel-coronavirus-covid-19/current-information. Accessed 6 January 2021.
- 381 9. Snijder MB, Galenkamp H, Prins M, Derks EM, Peters RJG, Zwinderman AH, et al. Cohort
- 382 profile: the Healthy Life in an Urban Setting (HELIUS) study in Amsterdam, The Netherlands. BMJ
- 383 Open. 2017;7(12):e017873.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21252788; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

384	10.	GeurtsvanKessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM, et al. An
385	evalua	tion of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat
386	Comm	un. 2020;11(1):3436.
387	11.	Dutch Government. Nieuwe maatregelen tegen verspreiding coronavirus in Nederland, 12
388	March	2020. Available from: https://www.rijksoverheid.nl/actueel/nieuws/2020/03/12/nieuwe-
389	maatre	gelen-tegen-verspreiding-coronavirus-in-nederland. Accessed 27 January 2021.
390	12.	Galenkamp H, van Oers H, Stronks K. To what extent do socioeconomic inequalities in SRH
391	reflect	inequalities in burden of disease? The HELIUS study. J Public Health (Oxf). 2020;42(4):e412-
392	e20.	
393	13.	Dutch Government. Dutch measures against coronavirus: Rules that apply indoors and
394	outdoo	ors. Available from: https://www.government.nl/topics/coronavirus-covid-19/tackling-new-
395	corona	virus-in-the-netherlands/public-life. Accessed 27 January 2021.

396 14. Vos ERA, den Hartog G, Schepp RM, Kaaijk P, van Vliet J, Helm K, et al. Nationwide

397 seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the

398 Netherlands during the first epidemic wave. J Epidemiol Community Health. 2020.

399 15. Liu T, Gong D, Xiao J, Hu J, He G, Rong Z, et al. Cluster infections play important roles in the

400 rapid evolution of COVID-19 transmission: A systematic review. International journal of infectious

401 diseases : IJID : official publication of the International Society for Infectious Diseases. 2020;99:374-

402 80.

403 16. James A, Eagle L, Phillips C, Hedges DS, Bodenhamer C, Brown R, et al. High COVID-19
404 Attack Rate Among Attendees at Events at a Church - Arkansas, March 2020. MMWR Morb Mortal
405 Wkly Rep. 2020;69(20):632-5.

Yong SEF, Anderson DE, Wei WE, Pang J, Chia WN, Tan CW, et al. Connecting clusters of
COVID-19: an epidemiological and serological investigation. Lancet Infect Dis. 2020;20(7):809-15.
Lukman AF, Rauf RI, Abiodun O, Oludoun O, Ayinde K, Ogundokun RO. COVID-19
prevalence estimation: Four most affected African countries. Infect Dis Model. 2020;5:827-38.

20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

- 410 19. Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al. Seroprevalence of
- 411 anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science. 2021;371(6524):79-82.
- Ng KA-O, Faulkner NA-O, Cornish GA-O, Rosa AA-O, Harvey R, Hussain SA-OX, et al. 412 20.
- 413 Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science.
- 414 2020;370(6522):1339-43.
- Sette A, Crotty SA-O. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. 415 21.
- 416 Nat Rev Immunol. 2020;20(8):457-8.
- 417 22. Madewell ZJ, Yang Y, Longini IM, Jr., Halloran ME, Dean NE. Household Transmission of
- SARS-CoV-2: A Systematic Review and Meta-analysis. JAMA Network Open. 2020;3(12):e2031756-418
- 419 e.
- 420 Shen M, Peng Z, Guo Y, Rong L, Li Y, Xiao Y, et al. Assessing the effects of metropolitan-23.
- wide quarantine on the spread of COVID-19 in public space and households. Int J Infect Dis. 421
- 422 2020;96:503-5.
- Sun K, Wang W, Gao L, Wang Y, Luo K, Ren L, et al. Transmission heterogeneities, kinetics, 423 24.
- and controllability of SARS-CoV-2. Science. 2021;371(6526):eabe2424. 424
- 425 Organisation for Economic Co-operation and Development. Health for Everyone? Social 25.
- 426 Inequalities in Health and Health Systems. Paris, France: OECD Health Policy Studies; 2019.
- Cover L, Wynberg E, Buster M, Wijffels C, Prins M, Schreijer A, et al. The first wave of 427 26.
- 428 COVID-19 in the greater Amsterdam area, the Netherlands. Presented at: ESCMID Conference on
- 429 Coronavirus Disease (ECCVID), 23-25 September 2020.
- Kunst A, de Visser M, Stoeldraijer L, Harmsen C. Oversterfte tijdens de eerste zes weken 430 27.
- 431 van de corona-epidemie: Sociaal-demografische en geografische verschillen. Centraal Bureau voor
- Statistiek; 2020. Available from: https://www.cbs.nl/nl-nl/achtergrond/2020/20/oversterfte-tijdens-432
- de-eerste-zes-weken-van-de-corona-epidemie. 433

medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21252788; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pernetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

- 434 28. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,
- 435 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA.
- 436 2020;324(8):782-93.
- 437 29. Raharja A, Tamara A, Kok LT. Association Between Ethnicity and Severe COVID-19 Disease:
- 438 a Systematic Review and Meta-analysis. J Racial Ethn Health Disparities. 2020:1-10.
- 439 30. Webb Hooper M, Nápoles AM, Pérez-Stable EJ. COVID-19 and Racial/Ethnic Disparities.
- 440 JAMA. 2020;323(24):2466-7.
- 441 31. Egede LE, Walker RJ. Structural Racism, Social Risk Factors, and Covid-19 A Dangerous
- 442 Convergence for Black Americans. New England Journal of Medicine. 2020;383(12):e77.
- 443 32. Bambra C, Riordan R, Ford J, Matthews F. The COVID-19 pandemic and health inequalities.
- Journal of Epidemiology and Community Health. 2020;74(11):964.
- 445 33. Schmengler H, Ikram UZ, Snijder MB, Kunst AE, Agyemang C. Association of perceived
- ethnic discrimination with general and abdominal obesity in ethnic minority groups: the HELIUS
- study. J Epidemiol Community Health. 2017;71(5):453-60.
- 448 34. Suurmond J, Rosenmöller DL, El Mesbahi H, Lamkaddem M, Essink-Bot ML. Barriers in
- 449 access to home care services among ethnic minority and Dutch elderly--a qualitative study. Int J
- 450 Nurs Stud. 2016;54:23-35.
- 451 35. National Institute for Public Health and the Environment. PIENTER Corona studie:
- 452 Resultaten. Available from: https://www.rivm.nl/pienter-corona-studie/resultaten. Accessed 22
- 453 February 2021.
- 454 36. Dutch Government. Vermijd drukte, houd 1,5 meter afstand 2020, 6 May 2020. Available
- 455 from: https://www.rijksoverheid.nl/actueel/nieuws/2020/05/06/vermijd-drukte-houd-15-meter-
- 456 afstand. Accessed 6 January 2021.
- 457 37. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid
- 458 Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med.
- 459 2020;383(11):1085-7.

20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

- 460 38. Choe PG, Kim KH, Kang CK, Suh HJ, Kang E, Lee SY, et al. Antibody Responses 8 Months
- 461 after Asymptomatic or Mild SARS-CoV-2 Infection. Emerg Infect Dis. 2020;27(3).
- 462 Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust 39.
- neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370(6521):1227. 463
- 464 Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. 40.
- 465 Humoral Immune Response to SARS-CoV-2 in Iceland. New England Journal of Medicine.
- 466 2020;383(18):1724-34.
- 467

469 **Tables**

470 Table 1. Characteristics of the HELIUS participants included in the COVID-19 study, by ethnic group (N=2497), Amsterdam, the Netherlands, 24

471 June - 9 October 2020

Characteristic	Dutch (n=503)	South-Asian Surinamese (n=453)	African Surinamese (n=407)	Ghanaian (n=331)	Turkish (n=409)	Moroccan (n=392)	
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	P-value
Sex							
Male	237 (47.1%)	179 (39.5%)	165 (40.5%)	145 (43.8%)	184 (45.0%)	173 (43.9%)	0.19
Female	266 (52.9%)	274 (60.5%)	242 (59.5%)	186 (56.2%)	225 (55.0%)	221 (56.1%)	
Age in years on 1 January 2020							
Median [IQR]	57 [45-66]	56[47-63]	59 [50-65]	54 [47-59]	48 [40-56]	49 [39-56]	<0.001
Migration generation							
1 st	N.A.	370 (81.7%)	355 (87.2%)	325 (98.2%)	306 (74.8%)	300 (76.1%)	<0.001
2 nd	N.A	83 (18.3%)	52 (12.8%)	6 (1.8%)	103 (25.2%)	94 (23.9%)	
City district ^a							
Centre	88 (17.5%)	18 (4.0%)	15 (3.7%)	5 (1.5%)	4 (1.0%)	12 (3.0%)	<0.001
East	99 (19.7%)	53 (11.7%)	84 (20.6%)	25 (7.6%)	66 (16.1%)	94 (23.9%)	
West	89 (17.7%)	6 (1.3%)	34 (8.4%)	19 (5.7%)	66 (16.1%)	83 (21.1%)	
South	112 (22.3%)	32 (7.1%)	28 (6.9%)	8 (2.4%)	30 (7.3%)	38 (9.6%)	
New-West	45 (8.9%)	111 (24.5%)	51 (12.5%)	18 (5.4%)	231 (56.5%)	147 (37.3%)	
Southeast	65 (12.9%)	229 (50.6%)	192 (47.2%)	254 (76.7%)	6 (1.5%)	19 (4.8%)	
Other/missing	5 (1.0%)	4 (0.9%)	3 (0.7%)	2 (0.6%)	6 (1.5%)	1(0.3%)	
Educational level ^a							
No school/elementary school Lower vocational/lower	10 (2.0%)	56 (12.4%)	15 (3.7%)	78 (23.6%)	78 (19.1%)	90 (22.8%)	<0.001
secondary school Intermediary vocational/intermediary	56 (11.1%)	156 (34.4%)	124 (30.5%)	128 (38.7%)	84 (20.5%)	64 (16.2%)	
secondary school	99 (19.7%)	137 (30.2%)	142 (34.9%)	73 (22.1%)	124 (30.3%)	125 (31.7%)	
Higher vocational/university	337 (67.0%)	103 (22.7%)	124 (30.5%)	26 (7.9%)	108 (26.4%)	94 (23.9%)	

20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

Missing	1 (0.2%)	1(0.2%)	2 (0.5%)	26 (7.9%)	15 (3.7%)	21 (5.3%)	
Labor participation ^b							
Employed	380 (75.5%)	308 (68.0%)	292 (71.7%)	203 (61.3%)	247 (60.4%)	229 (58.1%)	<0.001
Not in workforce	90 (17.9%)	47 (10.4%)	40 (9.8%)	10 (3.0%)	59 (14.4%)	63 (16.0%)	
Unemployed/on benefits	21 (4.2%)	53 (11.7%)	47 (11.5%)	60 (18.1%)	62 (15.2%)	57 (14.5%)	
Disabled	11 (2.2%)	39 (8.6%)	24 (5.9%)	28 (8.5%)	27 (6.6%)	22 (5.6%)	
Unknown/missing	1 (0.2%)	6 (1.3%)	4 (1.0%)	30 (9.0%)	14 (3.4%)	23 (5.8%)	
Occupational level ^a							
Elementary occupations	5 (1.0%)	36 (7.9%)	22 (5.4%)	162 (48.9%)	52 (12.7%)	46 (11.7%)	<0.001
Lower occupations	46 (9.1%)	127 (28.0%)	101 (24.8%)	69 (20.8%)	102 (24.9%)	92 (23.4%)	
Intermediary occupations	107 (21.3%)	143 (31.6%)	146 (35.9%)	21 (6.3%)	88 (21.5%)	94 (23.9%)	
Higher occupations	203 (40.4%)	79 (17.4%)	91 (22.4%)	11 (3.3%)	51 (12.5%)	65 (16.5%)	
Scientific occupations	115 (22.9%)	20 (4.4%)	19 (4.7%)	6 (1.8%)	32 (7.8%)	10 (2.5%)	
Missing	27 (5.4%)	48 (10.6%)	28 (6.9%)	62 (18.7%)	84 (22.5%)	87 (22.1%)	
Job setting ^b		• • •				,	
No job / caretaker only	117 (23.3%)	144 (31.8%)	120 (29.5%)	90 (27.2%)	138 (33.7%)	132 (33.5%)	<0.001
Job with no contact within 1.5							
meter	96 (19.1%)	65 (14.3%)	39 (9.6%)	66 (19.9%)	67 (16.4%)	54 (13.7%)	
Other job with contact within							
1.5 meter	145 (28.8%)	154 (34.0%)	131 (32.2%)	115 (34.7%)	130 (31.8%)	114 (28.9%)	
Child care/schools/higher							
education	62 (12.3%)	27 (6.0%)	43 (10.6%)	10 (3.0%)	25 (6.1%)	48 (12.2%)	
Bar/restaurant	12 (2.4%)	10 (2.2%)	11 (2.7%)	23 (6.9%)	6 (1.5%)	7 (1.8%)	
Hospital/long-term care							
facility/Health care worker							
elsewhere	71 (14.1%)	51 (11.3%)	63 (15.5%)	26 (7.9%)	41 (10.0%)	36 (9.1%)	
Missing	o (o.o%)	2 (0.4%)	o (o.o%)	1(0.3%)	2 (0.5%)	3 (0.8%)	
Difficulty with Dutch							
languageª			(00.04)	<i>(</i>) ()		(<u>60</u> ()	
No	N.A.	348 (76.8%)	359 (88.2%)	41 (12.4%)	189 (46.2%)	211 (53.6%)	<0.001
Yes	N.A.	104 (23.0%)	46 (11.3%)	264 (79.8%)	206 (50.4%)	162 (41.1%)	
Missing	N.A.	1(0.2%)	2 (0.5%)	26 (7.9%)	14 (3.4%)	21 (5.3%)	
Health literacy (SBSQ) ^a							
Adequate	500 (99.4%)	437 (96.5%)	400 (98.3%)	209 (63.1%)	310 (75.8%)	308 (78.2%)	<0.001
Low	3 (0.6%)	16 (3.5%)	7 (1.7%)	97 (29.3%)	87 (21.3%)	64 (16.2%)	

Missing	o (o.o%)	o (o.o%)	o (o.o%)	25 (7.6%)	12 (2.9%)	22 (5.6%)	
Diabetes mellitus ^c							
No	478 (95.0%)	358 (79.0%)	362 (88.9%)	297 (89.7%)	366 (89.5%)	345 (87.6%)	<0.001
Yes	18 (3.6%)	88 (19.4%)	42 (10.3%)	30 (9.1%)	35 (8.6%)	41 (10.4%)	
Missing	7 (1.4%)	7 (1.5%)	3 (0.7%)	4 (1.2%)	8 (2.0%)	8 (2.0%)	
High blood pressure ^d							
No	370 (73.6%)	261 (57.6%)	198 (48.6%)	143 (43.2%)	321 (78.5%)	305 (77.4%)	<0.001
Yes	127 (25.2%)	185 (40.8%)	207 (50.9%)	181 (54.7%)	82 (20.0%)	81 (20.6%)	
Missing	6 (1.2%)	7 (1.5%)	2 (0.5%)	7 (2.1%)	6 (1.5%)	8 (2.0%)	
Body Mass Index (kg/m2),							<0.001
median (IQR)ª	24 [22-27]	25 [23-28]	27 [24-29]	28 [25-31]	27 [24-31]	27 [24-30]	
Month of study visit ^b							
June	86 (17.1%)	44 (9.7%)	31 (7.6%)	o (o.o%)	o (o.o%)	32 (8.1%)	<0.001
July	265 (52.7%)	233 (51.4%)	203 (49.9%)	38 (11.5%)	151 (36.9%)	170 (43.1%)	
August	108 (21.5%)	98 (21.6%)	110 (27.0%)	135 (40.8%)	88 (21.5%)	85 (21.6%)	
September	39 (7.8%)	75 (16.6%)	56 (13.8%)	125 (37.8%)	127 (31.1%)	74 (18.8%)	
October	5 (1.0%)	3 (0.7%)	7 (1.7%)	33 (10.0%)	43 (10.5%)	33 (8.4%)	

472 Abbreviations: BMI, body mass index; HELIUS, Healthy Life in an Urban Setting; IQR, interquartile range; N.A., not applicable; SBSQ, Set of Brief Screening Question ^a Presumed higher

473 exposure categories had priority, i.e. if someone was working in a school and as a health care worker, they were categorized as a health care worker. Caretakers were not included as a

474 category because many had other jobs.

475 ^a Measured at baseline (2011-2015) ^b Measured at COVID-1 visit (2020) ^c Based on self-report, increased fasting glucose (≥7 mmol/l) or use of glucose-lowering medication ^d Based on self-

476 report, SBP ≥140 mmHg, DBP ≥90 or blood pressure-lowering medication

Table 2. SARS-CoV-2-related characteristics of the HELIUS participants included in the COVID-19 study, by ethnicity (N=2497), Amsterdam, the

478 Netherlands, 24 June - 9 October 2020

Characteristic		South-Asian	African				
	Dutch	Surinamese	Surinamese	Ghanaian	Turkish	Moroccan	
	(n=503)	(n=453)	(n=407)	(n=331)	(n=409)	(n=392)	
	n (%)	P-value					
Do you think you have been infected?							
(among all respondents)							
Yes, this was confirmed by a PCR test	1(0.2%)	4 (0.9%)	5 (1.2%)	2 (0.6%)	5 (1.2%)	9 (2.3%)	<0.001
Yes, this was confirmed by a Ab test	6 (1.2%)	1(0.2%)	1(0.2%)	o (o.o%)	1(0.2%)	2 (0.5%)	
Yes, but this was not confirmed by a test	67 (13.3%)	46 (10.2%)	51 (12.5%)	16 (4.8%)	63 (15.4%)	68 (17.3%)	
No, this was confirmed by a PCR test	28 (5.6%)	22 (4.9%)	22 (5.4%)	14 (4.2%)	26 (6.4%)	17 (4.3%)	
No, this was confirmed by a Ab test	6 (1.2%)	4 (0.9%)	5 (1.2%)	2 (0.6%)	5 (1.2%)	9 (2.3%)	
No, I do not think so, but this was not							
confirmed by a test	178 (35.4%)	181 (40.0%)	139 (34.2%)	90 (27.2%)	112 (27.4%)	108 (27.4%)	
No, I know for certain, because I did not							
have any symptoms	178 (35.4%)	152 (33.6%)	144 (35.4%)	182 (55.0%)	134 (32.8%)	144 (36.5%)	
I do not know	39 (7.8%)	41 (9.1%)	40 (9.8%)	25 (7.6%)	61 (14.9%)	36 (9.1%)	
Missing	0 (0.0%)	2 (0.4%)	o (o.o%)	0 (0.0%)	2 (0.5%)	1 (0.3%)	
Do you think you have been infected?							<0.001
(among SARS-CoV-2 antibody positive							
individuals)							
No/do not know	6 (24.0%)	9 (40.9%)	4 (18.2%)	86 (90.5%)	11 (36.7%)	13 (40.6%)	
Yes	19 (76.0%)	13 (59.1%)	18 (81.8%)	9 (9.5%)	19 (63.3%)	19 (59.4%)	
Thinks household member/steady partner							<0.001
was infected							
N.A.	93 (18.5%)	89 (19.6%)	104 (25.6%)	40 (12.1%)	50 (12.2%)	58 (14.7%)	
No	352 (70.0%)	321 (70.9%)	270 (66.3%)	275 (83.1%)	310 (75.8%)	281 (71.3%)	
Yes	53 (10.5%)	38 (8.4%)	33 (8.1%)	15 (4.5%)	46 (11.2%)	51 (12.9%)	
Missing	5 (1.0%)	5 (1.1%)	0 (0.0%)	1 (0.3%)	3 (0.7%)	4 (1.0%)	
Household member hospitalized for							<0.001
COVID-19							
N.A.	93 (18.5%)	89 (19.6%)	104 (25.6%)	40 (12.1%)	50 (12.2%)	58 (14.7%)	
No	401 (79.7%)	356 (78.6%)	302 (74.2%)	290 (87.6%)	352 (86.1%)	329 (83.5%)	

4 (0.8%)	3 (0.7%)	1 (0.2%)	o (o.o%)	4 (1.0%)	3 (0.8%)	
5 (1.0%)	5 (1.1%)	o (o.o%)	1(0.3%)	3 (0.7%)	4 (1.0%)	
						<0.001
59 (11.7%)	144 (31.8%)	145 (35.6%)	122 (36.9%)	106 (25.9%)	101 (25.6%)	
82 (16.3%)	134 (29.6%)	99 (24.3%)	120 (36.3%)	97 (23.7%)	90 (22.8%)	
141 (28.0%)	103 (22.7%)	80 (19.7%)	58 (17.5%)	103 (25.2%)	88 (22.3%)	
221 (43.9%)	70 (15.5%)	83 (20.4%)	30 (9.1%)	101 (24.7%)	113 (28.7%)	
0 (0.0%)	2 (0.4%)	0 (0.0%)	1(0.3%)	2 (0.5%)	2 (0.5%)	
216 (42.9%)	218 (48.1%)	192 (47.2%)	239 (72.2%)	207 (50.6%)	209 (53.0%)	<0.001
89 (17.7%)	80 (17.7%)	84 (20.6%)	43 (13.0%)	48 (11.7%)	45 (11.4%)	
146 (29.0%)	120 (26.5%)	97 (23.8%)	41 (12.4%)	110 (26.9%)	102 (25.9%)	
49 (9.7%)	30 (6.6%)		6 (1.8%)	41 (10.0%)	34 (8.6%)	
3 (0.6%)	5 (1.1%)	2 (0.5%)	2 (0.6%)	3 (0.7%)	4 (1.0%)	
	5(1.0%) 59(11.7%) 82(16.3%) 141(28.0%) 221(43.9%) 0(0.0%) 216(42.9%) 89(17.7%) 146(29.0%) 49(9.7%)	5(1.0%) $5(1.1%)$ $59(11.7%)$ $144(31.8%)$ $82(16.3%)$ $134(29.6%)$ $141(28.0%)$ $103(22.7%)$ $221(43.9%)$ $70(15.5%)$ $0(0.0%)$ $2(0.4%)$ $216(42.9%)$ $218(48.1%)$ $89(17.7%)$ $80(17.7%)$ $146(29.0%)$ $120(26.5%)$ $49(9.7%)$ $30(6.6%)$	5(1.0%) $5(1.1%)$ $0(0.0%)$ $59(11.7%)$ $144(31.8%)$ $145(35.6%)$ $82(16.3%)$ $134(29.6%)$ $99(24.3%)$ $141(28.0%)$ $103(22.7%)$ $80(19.7%)$ $221(43.9%)$ $70(15.5%)$ $83(20.4%)$ $0(0.0%)$ $2(0.4%)$ $0(0.0%)$ $216(42.9%)$ $218(48.1%)$ $192(47.2%)$ $89(17.7%)$ $80(17.7%)$ $84(20.6%)$ $146(29.0%)$ $120(26.5%)$ $97(23.8%)$ $49(9.7%)$ $30(6.6%)$ $32(7.9%)$	5(1.0%) $5(1.1%)$ $0(0.0%)$ $1(0.3%)$ $59(11.7%)$ $144(31.8%)$ $145(35.6%)$ $122(36.9%)$ $82(16.3%)$ $134(29.6%)$ $99(24.3%)$ $120(36.3%)$ $141(28.0%)$ $103(22.7%)$ $80(19.7%)$ $58(17.5%)$ $221(43.9%)$ $70(15.5%)$ $83(20.4%)$ $30(9.1%)$ $0(0.0%)$ $2(0.4%)$ $0(0.0%)$ $1(0.3%)$ $216(42.9%)$ $218(48.1%)$ $192(47.2%)$ $239(72.2%)$ $89(17.7%)$ $80(17.7%)$ $84(20.6%)$ $43(13.0%)$ $146(29.0%)$ $120(26.5%)$ $97(23.8%)$ $41(12.4%)$ $49(9.7%)$ $30(6.6%)$ $32(7.9%)$ $6(1.8%)$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$


479 Abbreviations: HELIUS, Healthy Life in an Urban Setting

20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

Figures 480

Figure 1. Flowchart depicting the selection of HELIUS participants in the COVID-19 study, 481


Amsterdam, the Netherlands, 24 June - 9 October 2020 482




20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

485 Figure 2. Unadjusted and adjusted SARS-CoV-2 seroprevalence per ethnic group (N=2475),

486 Amsterdam, the Netherlands, 24 June - 9 October 2020



487



489 calculation. Boxes represent the seroprevalence estimate, bands the corresponding 95% confidence

490 interval. Adjusted seroprevalence estimates were corrected for sampling, accounted for the


491 population structure of ethnic groups in Amsterdam (i.e. post-stratification), and adjusted for


- differences in age, sex and calendar time (before/after 15 August 2020) between ethnic groups. 492
- 493

20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

494 Figure 3. SARS-CoV-2 seroprevalence and age by ethnic group, Amsterdam, the Netherlands,

495 24 June - 9 October 2020





497 sample and post-stratification weights, within subpopulations of ethnic groups.

20210222-HELIUS COVID-19 manuscript seroprevalence-vs6.3_refs_ethics

Figure 4. Determinants of SARS-CoV-2 seropositivity by ethnic group, HELIUS COVID-19 study, 499

500 24 June - 9 October 2020 (multivariable analysis)

Ethnicity and determinants		aOR (95%CI)	P-valu
Dutch			
Household member with suspected infection	─	5.89 (2.13-16.28)	0.001
Picked up medication/doctor visit past week		3.38 (1.11-10.29)	0.032
Travelled abroad in 2020		5.04 (1.74-14.57)	0.003
South Asian Surinamese			
Household member with suspected infection	→	6.19 (1.85-20.78)	0.003
Travelled abroad in 2020		3.79 (1.85-11.01)	0.015
African Surinamese			
Lives with other adults	— —	8.75 (2.03-37.77)	0.004
≥2 visitors past week		4.59 (1.61-13.11)	0.005
Ghanaian			
Age (per year)	•	1.06 (1.03-1.08)	<0.001
Household size (per person)	+	1.42 (1.13-1.78)	0.003
With children ≤3 years old		3.42 (1.23-9.51)	0.018
Went to work past week	— •—	2.05 (1.07-3.92)	0.031
Religious service past week		2.36 (1.28-4.37)	0.006
Turkish			
Household member with suspected infection	→	11.15 (4.40-28.25)	<0.001
Walk or exercise outside past week		4.08 (1.68-9.89)	0.002
Public transport past week		2.99 (1.15-7.78)	0.024
Morrocan			
Household member with suspected infection		5.43 (2.04-14.40)	0.001
Occupational level			
No elementary occupation	+	Ref.	0.009
Elementary occupation	+•	1.76 (0.50-6.23)	
Missing occupation		4.47 (1.68-11.90)	
.2 .5	1 1 2 5 10 25 5 aOR (95%CI)	0	

501